EMERCell Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
3
- Latest Deal Type
-
M&A
- Investors
-
1
EMERCell General Information
Description
Developer of an immunotherapy product intended to implement the first steps of the pharmaceutical development. The company develops cell therapy products for oncology, advanced therapy medicinal products using a patented process to amplify and activate allogeneic natural killer cells used in association with monoclonal antibodies, thereby enabling patients to access off-the-shelf, scalable, and reproducible cell-based therapies with consistent potency and safety profiles.
Contact Information
Website
www.emercell.com(Operating Subsidiary)
Corporate Office
- 77 rue de Vaugirard
- 75006 Paris
- France
Corporate Office
- 77 rue de Vaugirard
- 75006 Paris
- France
EMERCell Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 17-Feb-2021 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
EMERCell Patents
EMERCell Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2998292-A1 | Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease | Active | 11-Sep-2015 | ||
| EP-3347454-A1 | Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease | Pending | 11-Sep-2015 | ||
| US-12291574-B2 | Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease | Active | 11-Sep-2015 | ||
| US-20170281681-A1 | Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease | Inactive | 11-Sep-2015 | ||
| US-20220096554-A1 | Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease | Active | 11-Sep-2015 | C07K16/2887 |
EMERCell Signals
EMERCell FAQs
-
When was EMERCell founded?
EMERCell was founded in 2013.
-
Where is EMERCell headquartered?
EMERCell is headquartered in Paris, France.
-
What is the size of EMERCell?
EMERCell has 3 total employees.
-
What industry is EMERCell in?
EMERCell’s primary industry is Drug Discovery.
-
Is EMERCell a private or public company?
EMERCell is a Private company.
-
What is EMERCell’s current revenue?
The current revenue for EMERCell is .
-
When was EMERCell acquired?
EMERCell was acquired on 17-Feb-2021.
-
Who acquired EMERCell?
EMERCell was acquired by Onward Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process